CNS Therapeutics Market (Disease Type - Neurovascular Disease, Trauma, Mental Health, Degenerative, Infections, and Cancer; Application - Hospitals, Clinics, Home Care, and Others): Global Industry Analysis, Trends, Size, Share and Forecasts to 2026

A recent report published by Infinium Global Research on the CNS therapeutics market provides an in-depth analysis of segments and sub-segments in the global as well as regional CNS therapeutics market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional CNS therapeutics market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast, and dollar values of the global CNS therapeutics market. According to the report, the global CNS therapeutics market is projected to grow at a CAGR of 4.36% over the forecast period of 2020-2026.

Market Insight

The central nervous system is a critical part of the human body. CNS diseases disturb the operation of the brain and can affect the neuronal structure. Technological progressions in therapy are made for a better understanding of the pathogenesis of CNS diseases and therefore CNS therapeutics are mainly being used in the treatment of neurological disorders and chronic pain. The recent outbreak of coronavirus infectious has gripped the world with apprehension and infected humans worldwide. The current concerns over the spread of coronavirus are expected to have a moderate impact on the growth of the CNS therapeutics market as the demand is totally dependent on neurological and mental illness. However, several COVID-19 patients are at the risk of developing neurological symptoms in addition to common respiratory symptoms as established by a retrospective case series study in Wuhan, China, which shows patients with severe COVID-19 develop more neurological symptoms such as acute cerebrovascular accidents, altered level of consciousness, and skeletal muscle damage as compared to those with a mild infection, which in turn may propel the demand of CNS therapeutics market. Nevertheless, the market will accelerate owing to increasing healthcare awareness and increasing the adoption of advanced therapies.

The global rise in the incidence of neurological illnesses is a key driving factor in the growth of the CNS therapeutics market. A rise in the old age population including Alzheimer’s and Multiple sclerosis coupled with growing healthcare expenditures is driving the global demand for CNS therapeutics. The progress of the CNS therapeutics market is further driven by parameters such as innovations in diagnosis, treatments, and drug discovery procedures. Recent technological advancement in neurological imaging which helps in early diagnosing of the disorders is another key factor driving the growth of the CNS therapeutics market. An increase in initiatives by government and non-government organizations which has caused increased awareness regarding neurodegenerative diseases fuel market growth. The global CNS therapeutics market is likely to be driven by a high occurrence of these disorders, and growth in the awareness about CNS treatments. Growing focus on regenerative therapies which helps in healing by regeneration of human cells, tissues or organ propels the growth of CNS therapeutics market in the forecast period. Thus, key players are focusing on the development of regenerative therapy owing to the increase in preference of these therapies among patients. However, several side effects of the CNS therapeutics restrain the growth of the market.

Geographically, North America holds the largest share of the market and anticipated to maintain its dominance over the forecast period. Rising awareness among the people about mental disorders and their treatments and the availability of innovative healthcare structures contributes to the growth of the region. The market in Europe will escalate over the rising prevalence of awareness campaigns and conferences about the identification and treatment of CNS diseases propel the market. CNS therapeutics market in the Asia Pacific is anticipated to witness significant growth due to a high rate of prevalence of neurodegenerative disorders, and improvements in healthcare facilities.

Segment Covered

The report on the global CNS therapeutics market covers segments such as disease type, and application. On the basis of disease type, the sub-markets include neurovascular disease, trauma, mental health, degenerative, infections, and cancer. On the basis of application, the sub-markets include hospitals, clinics, home care, and others.

Companies Profiled:

The report provides profiles of the companies in the market such as Pfizer Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., Johnson & Johnson Services Inc., Eli Lilly and Company, Novartis AG, Pharmaceutical Industries Ltd., AstraZeneca, Merck & Co., Inc., and Otsuka America Pharmaceutical, Inc.

Report Highlights:

The report provides deep insights into the demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of CNS therapeutics market. Moreover, the study highlights current market trends and provides forecast from 2020-2026. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.